Synthetic androgens in male hormonal contraception: perspectives and unresolved issues
Clinical review for general practice · 19.06.2026 · 7 (4) · 104-109
DOI: 10.47407/kr2026.7.4.00829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 19.06.2026. Verfasst von Alfija R Khaibullina und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Over the past decades, the development of male hormonal contraceptives (MHCs) has become a priority in reproductive medicine. Despite the availability of only two established male methods–condoms and vasectomy–there remains a significant unmet need for novel, safe, and reversible contraceptive options. Sociological surveys consistently demonstrate men’s willingness to take greater responsibility for fertility control, with particular interest in oral formulations and long-acting implants. The principle of MHCs is based on the administration of exogenous androgens, usually in combination with progestins, which suppress the hypothalamic–pituitary–gonadal axis and spermatogenesis while maintaining peripheral androgenic effects. Synthetic androgens such as 7α-methyl-19-nortestosterone (MENT), 7α,11β-dimethyl-19-nortestosterone undecanoate (DMAU), and 11β-methyl-19-nortestosterone-17β-dodecylcarbonate (11βMNTDC) possess unique pharmacological properties, including resistance to 5α-reductase, lack of aromatization, and a more favorable prostate safety profile. Preclinical and clinical studies have shown that these agents can induce reversible suppression of spermatogenesis and maintain androgenic activity with minimal side effects. Nevertheless, several critical issues remain unresolved, including the need to demonstrate consistent, long-term suppression of sperm production at clinically acceptable doses, as well as to assess potential long-term effects on bone health and metabolism. Progress in this field requires coordinated efforts among researchers, clinicians, the pharmaceutical industry, and regulatory agencies. The successful development of safe, effective, and reversible MHCs would not only broaden the range of contraceptive options but also promote shared responsibility for reproductive decision-making between men and women. Keywords: male contraception, hormonal contraception, synthetic androgens, testosterone, MENT, DMAU, 11βMNTDC.
Zitieren
APA
Khaibullina, A. R., Shutilova, K. A., Vasilyeva, A. A., Aglyamutdinova, D. R., & Yakupova, G. I. (2026). Synthetic androgens in male hormonal contraception: perspectives and unresolved issues. Clinical review for general practice, 7(4), 104-109. https://doi.org/10.47407/kr2026.7.4.00829
Vancouver
Khaibullina AR, Shutilova KA, Vasilyeva AA, Aglyamutdinova DR, Yakupova GI. Synthetic androgens in male hormonal contraception: perspectives and unresolved issues. Clinical review for general practice. 2026;7(4):104-109. doi:10.47407/kr2026.7.4.00829
BibTeX
@article{Khaibullina2026,
author = {Khaibullina, Alfija R and Shutilova, Ksenia A and Vasilyeva, Alisa A and Aglyamutdinova, Diana R and Yakupova, Gulnaz I},
title = {Synthetic androgens in male hormonal contraception: perspectives and unresolved issues},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {4},
pages = {104--109},
doi = {10.47407/kr2026.7.4.00829}
}
EUVIMED